Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Department of Neuroscience DNS, Otolaryngology Section, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Int J Mol Sci. 2022 Jul 21;23(14):8053. doi: 10.3390/ijms23148053.
Programmed cell death ligand 1 (PD-L1) seems to rely on close relations between neoplastic and immune cells in the tumor microenvironment. Tumor to stroma ratio (TSR) has been associated with prognosis in different malignancies. The aims of this exploratory investigation were to analyze for the first time the: (i) association between TSR, PD-L1 expression and other clinical−pathological features in laryngeal squamous cell carcinoma (LSCC) biopsies and paired surgical specimens; (ii) prognostic and predictive role of TSR and PD-L1. TSR, PD-L1 expression (in terms of combined positive score [CPS]), and other clinical−pathological features were analyzed in biopsies and surgical specimens of 43 consecutive LSCC cases. A CPS < 1 evaluated on surgical specimens was associated with a low TSR (stroma rich) on both biopsies and surgical specimens (p = 0.0143 and p = 0.0063). Low TSR showed a significant negative prognostic value when evaluated on both biopsies and surgical specimens (HR = 8.808, p = 0.0003 and HR = 11.207, p = 0.0002). CPS ≥ 1 appeared to be a favorable prognostic factor (HR = 0.100, p = 0.0265). The association between bioptic and surgical specimen TSR and PD-L1 expression should be further investigated for a potential impact on targeted treatments, also with regard to immunotherapeutic protocols.
程序性细胞死亡配体 1（PD-L1）似乎依赖于肿瘤微环境中肿瘤细胞与免疫细胞之间的密切关系。肿瘤与基质比（TSR）与不同恶性肿瘤的预后相关。本探索性研究的目的是首次分析：（i）在喉鳞状细胞癌（LSCC）活检和配对手术标本中，TSR、PD-L1 表达与其他临床病理特征之间的关系；（ii）TSR 和 PD-L1 的预后和预测作用。分析了 43 例连续 LSCC 病例的活检和手术标本中的 TSR、PD-L1 表达（以联合阳性评分[CPS]表示）和其他临床病理特征。手术标本上评估的 CPS < 1 与活检和手术标本上的低 TSR（富含基质）相关（p = 0.0143 和 p = 0.0063）。低 TSR 在活检和手术标本上评估时具有显著的负预后价值（HR = 8.808，p = 0.0003 和 HR = 11.207，p = 0.0002）。CPS ≥ 1 似乎是一个有利的预后因素（HR = 0.100，p = 0.0265）。需要进一步研究活检和手术标本 TSR 和 PD-L1 表达之间的关系，以评估其对靶向治疗的潜在影响，包括免疫治疗方案。
